26 Mar 2026

CRC Research Update — March 26, 2026

Creator: The CRC Digest
Published: 2026-03-26T11:40:18Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Atezolizumab plus FOLFOX shows promise for stage III mismatch repair-deficient colon cancer
A randomized trial evaluated adding the immunotherapy atezolizumab to standard FOLFOX chemotherapy for stage III colon cancer with mismatch repair deficiency (dMMR/MSI-H), a subset that typically responds well to immune checkpoint inhibitors. (New England Journal of Medicine)
Phase II trial compares FOLFIRI vs. FOLFOXIRI with ramucirumab in first-line metastatic CRC
The WJOG9216G (RECAST) study randomized patients with untreated metastatic colorectal cancer to receive either FOLFIRI or the triplet regimen FOLFOXIRI, both combined with ramucirumab instead of the more commonly used bevacizumab. (European Journal of Cancer)
Large analysis reveals sex differences in treatment efficacy and toxicity for metastatic CRC
Researchers analyzed 18,041 patients in the ARCAD CRC database to examine how sex affects outcomes and side effects from first-line chemotherapy for metastatic colorectal cancer, highlighting potential differences in how men and women respond to standard treatments. (European Journal of Cancer)
Meta-analysis evaluates accuracy of blood-based ctDNA tests for colorectal cancer screening
A systematic review synthesized evidence on how well circulating tumor DNA blood tests detect colorectal cancer in asymptomatic, average-risk populations compared to traditional screening methods. (Critical Reviews in Oncology/Hematology)
Case report: molecular complete response to regorafenib plus immunotherapy in MSS rectal cancer
A 50-year-old woman with advanced mismatch repair-proficient (pMMR/MSS) rectal cancer—a type typically resistant to immunotherapy—achieved molecular complete response with the RIN protocol combining regorafenib, ipilimumab, and nivolumab. (Therapeutic Advances in Medical Oncology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Symptom predictive value studied in under-50 colorectal cancer diagnosis
Study examined how well symptoms predict colorectal cancer in people under age 50, providing data to help clinicians decide when to pursue diagnostic workup in younger patients. (Cancer Epidemiology, Biomarkers & Prevention)
Tumor blood vessel patterns differ by age at colorectal cancer diagnosis
Researchers used advanced imaging to compare tumor vasculature in early-onset versus later-onset colorectal cancer, finding age-related differences in blood vessel characteristics. (British Journal of Cancer)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

FIT threshold variation affects screening accuracy worldwide
Study examined how different positivity cutoffs for fecal immunochemical testing (FIT) used across countries impact detection rates for colorectal cancer and advanced precancerous lesions. (EClinicalMedicine)
Model compares 10-year outcomes of stool DNA testing versus colonoscopy
Researchers modeled cumulative effectiveness over 10 years comparing three rounds of multitarget stool DNA testing to a single colonoscopy, accounting for real-world adherence patterns. (Journal of Medical Economics)

Today's research spans from new treatment combinations to screening accuracy—each study helping build a clearer picture of how to detect and treat colorectal cancer more effectively.

CRC Research Update

Subscribe to The CRC Digest